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A bs tr ac t
Background
Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a 
sustained virologic response to therapy with peginterferon alfa plus ribavirin.
Methods
In this randomized, phase 3 trial, we evaluated the addition of telaprevir to peginter-
feron alfa-2a plus ribavirin in patients with HCV genotype 1 infection who had no 
response or a partial response to previous therapy or who had a relapse after an initial 
response. A total of 663 patients were assigned to one of three groups: the T12PR48 
group, which received telaprevir for 12 weeks and peginterferon plus ribavirin for a total 
of 48 weeks; the lead-in T12PR48 group, which received 4 weeks of peginterferon plus 
ribavirin followed by 12 weeks of telaprevir and peginterferon plus ribavirin for a total 
of 48 weeks; and the control group (PR48), which received peginterferon plus ribavirin 
for 48 weeks. The primary end point was the rate of sustained virologic response, which 
was defined as undetectable HCV RNA 24 weeks after the last planned dose of a 
study drug.
Results
Rates of sustained virologic response were significantly higher in the two telaprevir 
groups than in the control group among patients who had a previous relapse (83% in 
the T12PR48 group, 88% in the lead-in T12PR48 group, and 24% in the PR48 group), 
a partial response (59%, 54%, and 15%, respectively), and no response (29%, 33%, and 
5%, respectively) (P<0.001 for all comparisons). Grade 3 adverse events (mainly anemia, 
neutropenia, and leukopenia) were more frequent in the telaprevir groups than in the 
control group (37% vs. 22%).
Conclusions
Telaprevir combined with peginterferon plus ribavirin significantly improved rates of 
sustained virologic response in patients with previously treated HCV infection, re-
gardless of whether there was a lead-in phase. (Funded by Tibotec and Vertex Phar-
maceuticals; REALIZE ClinicalTrials.gov number, NCT00703118.)
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A pproximately 60% of patients who are infected with hepatitis C virus (HCV) genotype 1 are not cured by 48 weeks of 
peginterferon alfa combined with ribavirin.1 Such 
patients fall into one of three categories: those who 
have no response to therapy, which is defined as 
a reduction of less than 2 log10 in HCV RNA lev-
els after 12 weeks of therapy2; those who have a 
partial response, which is defined as a reduction 
of at least 2 log10 in a patient who has always had 
detectable serum HCV RNA during therapy; and 
those who have a relapse, which is defined as 
undetectable serum HCV RNA at the end of treat-
ment but with subsequent virologic relapse.
In two recent phase 2 trials, telaprevir, an orally 
bioavailable inhibitor of the nonstructural 3/4A 
HCV protease,3 substantially enhanced rates of 
sustained virologic response when it was com-
bined with peginterferon plus ribavirin in patients 
who had received previous therapy.4,5 In this ran-
domized, double-blind, placebo-controlled, phase 
3 study, we assessed the efficacy and safety of the 
addition of telaprevir to a regimen of peginter-
feron plus ribavirin in patients with chronic HCV 
genotype 1 infection who did not have a sustained 
virologic response to previous treatment.
Me thods
Patients
From September 2008 through July 2010, we en-
rolled patients at study centers in 17 countries in 
Europe, South America, and North America, as well 
as in Israel, and Australia. All patients were be-
tween the ages of 18 and 70 years, had chronic HCV 
genotype 1 infection, did not have a sustained vi-
rologic response to one previous course of pegin-
terferon plus ribavirin despite receiving at least 
80% of the intended dose, and had well-charac-
terized data on the previous treatment. Eligible 
patients had detectable HCV RNA, had undergone 
liver biopsy within 18 months before screening, 
and had an absolute neutrophil count of at least 
1200 per cubic millimeter, a platelet count of at 
least 90,000 per cubic millimeter, and a hemoglo-
bin level of at least 12 g per deciliter for women and 
13 g per deciliter for men. Patients were excluded if 
they had decompensated liver disease, other causes 
of significant liver disease, or active cancer.
The protocol (which is available with the full 
text of this article at NEJM.org) was approved by 
the independent ethics committee at each partici-
pating study center (for a complete list, see the 
Supplementary Appendix, available at NEJM.org). 
The study was performed in accordance with the 
provisions of the Declaration of Helsinki and Good 
Clinical Practice guidelines. All patients provided 
written informed consent.
Study Design
Patients were stratified according to their baseline 
viral load (HCV RNA, <800,000 or ≥800,000 IU 
per milliliter) and type of previous response to 
peginterferon plus ribavirin (no response, partial 
response, or relapse). No response was defined 
as a reduction of less than 2 log10 in HCV RNA 
after 12 weeks of therapy. Partial response was 
defined as a reduction of 2 log10 or more in HCV 
RNA after 12 weeks of therapy but with detect-
able HCV RNA. Relapse was defined as undetect-
able HCV RNA at the end of a previous course of 
therapy with HCV RNA positivity thereafter.
Telaprevir (Tibotec) was administered orally at 
a dose of 750 mg every 8 hours; peginterferon alfa-
2a (Pegasys, Roche) was administered subcutane-
ously at a dose of 180 μg per week; and ribavirin 
(Copegus, Roche) was administered orally at a 
dose of 1000 to 1200 mg per day.
Patients were randomly assigned to one of two 
groups receiving telaprevir (with or without a lead-
in period of therapy with peginterferon alfa-2a 
plus ribavirin) or a control group that received 
placebo along with peginterferon alfa-2a plus riba-
virin in a 2:2:1 ratio. Randomization was per-
formed with the use of a centralized system 
according to a predefined randomization list, con-
structed through random permuted blocks. In 
the T12PR48 group, 266 patients were assigned 
to receive telaprevir, peginterferon, and ribavirin 
for 12 weeks, followed by placebo plus peginter-
feron and ribavirin for 4 weeks, and then pegin-
terferon plus ribavirin alone for 32 weeks. In the 
lead-in T12PR48 group, 264 patients were assigned 
to receive placebo, peginterferon, and ribavirin for 
4 weeks, followed by telaprevir plus peg interferon 
plus ribavirin for 12 weeks, and then peginter-
feron plus ribavirin alone for 32 weeks. In the PR48 
(control) group, 132 patients were assigned to 
receive placebo, peginterferon, and ribavirin for 
16 weeks, followed by peginterferon plus ribavi-
rin for 32 weeks. In all the groups, study drugs 
were administered for 48 weeks.
All study investigators, patients, and the spon-
sors were unaware of study-group assignments 
until all patients had reached week 72, unless un-
blinding was necessary for medical reasons. Re-
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sults of HCV RNA tests up to week 24 were 
masked and were monitored by an independent 
reviewer to assess whether patients had met a 
predefined stopping rule. Telaprevir was stopped 
if HCV RNA levels were greater than 100 IU per 
milliliter at weeks 4, 6, and 8 after the start of 
telaprevir treatment; in such cases, patients were 
able to continue receiving peginterferon plus riba-
virin. All treatment had to be discontinued if pa-
tients had less than a 2 log10 decrease in HCV RNA 
at week 12 in the T12PR48 group and the control 
group or at week 16 in the lead-in T12PR48 group 
or in cases of detectable HCV RNA at week 24 or 
36. Patients who discontinued telaprevir because 
of the stopping rule were considered to have had 
virologic failure.
Study Oversight
The first author participated in the development 
of the study design and protocol development with 
the study sponsors. The first author also wrote the 
first draft of the manuscript and vouches for the 
completeness and veracity of the data and data 
analyses, as well as the fidelity of the report to the 
trial protocol. Editorial assistance in the prepara-
tion of the manuscript was funded by Janssen 
Pharmaceuticals, the parent company of Tibotec. 
Peginterferon and ribavirin were purchased from 
the manufacturers. All authors reviewed and ap-
proved the final form of the manuscript and 
made the decision to submit it for publication.
Efficacy Assessments
We performed plasma HCV RNA quantification 
using the COBAS TaqMan assay (Roche), version 
2.0, which has a lower limit of quantification of 
25 IU per milliliter and a limit of detection of 10 IU 
per milliliter. HCV RNA levels were measured at 
screening, at baseline, on day 3, and during weeks 
1, 2, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 36, and 48, 
as well as at the time of early discontinuation, at 
follow-up visits 4, 12, and 24 weeks after end of 
treatment, and at week 72, even in patients who 
discontinued early.
Virologic Assessments
To analyze for resistant variants, HCV RNA was 
isolated from plasma, and the nonstructural 3/4A 
protease domains were amplified by reverse-tran-
scriptase polymerase-chain-reaction assay and se-
quenced. Analyses were performed on baseline 
samples and in cases of virologic failure (i.e., in 
cases of viral breakthrough or cases in which pa-
tients met a virologic stopping rule) or relapse. 
Viral breakthrough was defined as an increase of 
at least 1 log10 in HCV RNA from the nadir reached 
during treatment or an HCV RNA level of more 
than 100 IU per milliliter in patients whose viral 
load had previously been less than 25 IU per mil-
liliter during treatment. Telaprevir-resistant vari-
ants included V36A/M, T54A/S, R155I/K/M/T, and 
A156S/T/V.6
Safety Assessments
Data on all adverse events were collected through-
out the treatment period and at the safety follow-
up assessment 4 weeks after the administration 
of the last dose of a study drug. Serious adverse 
events continued to be monitored throughout the 
follow-up period. Laboratory assessments were per-
formed at the same time points as efficacy assess-
ments.
Guidance for the management and grading of 
rash was included according to the following crite-
ria: grade 1 (mild, localized to one or several sites), 
grade 2 (moderate, with a diffuse skin eruption 
involving up to 50% of body surface), and grade 
3 (severe, involving more than 50% of body sur-
face or rash with the appearance of major systemic 
signs or symptoms). For patients with grade 1 or 
2 rash, medical management was performed at the 
discretion of the investigator. For patients with 
grade 2 rash that progressed or did not improve 
or any grade 3 rash, telaprevir was discontinued 
while the patient continued to receive peginter-
feron plus ribavirin. The discontinuation of ribavi-
rin (with or without peginterferon) was then sug-
gested if the rash did not improve within 7 days 
after the discontinuation of telaprevir.
For the management of anemia, reductions 
in the ribavirin dose were made in accordance 
with drug labeling. Reductions in the telaprevir 
dose were prohibited, as was the use of erythro-
poietin-stimulating agents. If reductions in the 
ribavirin dose or discontinuation did not result 
in improvement in anemia, then telaprevir ther-
apy was stopped. An independent data and safety 
monitoring board analyzed safety data at pre-
defined time points during the study.
Primary and Secondary End Points
The primary end point was the proportion of pa-
tients with either a previous relapse or lack of a 
previous response who had a sustained virologic 
response (i.e., undetectable plasma HCV RNA 24 
weeks after the last planned administration of a 
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study drug). Secondary end points included the ef-
fect of lead-in treatment with peginterferon plus 
ribavirin on sustained virologic response, the pro-
portion of patients who had undetectable HCV 
RNA at 4 and 8 weeks, the proportion of patients 
who had a relapse, and the change from baseline 
in log10 HCV RNA.
Statistical Analysis
All analyses were performed on the intention-to-
treat principle in all patients who underwent ran-
domization and received at least one dose of a 
study drug. The analysis of the primary end point 
was based on a logistic-regression model that in-
cluded study group, the type of previous response 
(no response, partial response, or relapse), and 
their interaction as factors and the baseline viral 
RNA as a covariate. We used the Hochberg pro-
cedure to adjust for multiple comparisons. The 
primary objective was to show superior rates of 
sustained virologic response in each of the two tela-
previr study groups, as compared with the control 
group, separately in patients who had a previous 
relapse or did not have a virologic response (either 
no response or a partial response) to therapy.
The estimated study sample size of 650 pa-
tients was calculated on the basis of the primary 
objective to provide a power of 90%. The calcula-
tion was performed with the use of a two-sided 
continuity-corrected chi-square test. A P value of 
0.05 was considered to indicate statistical signifi-
cance. On the basis of the results of the Protease 
Inhibition for Viral Evaluation 3 (PROVE3) trial 
(ClinicalTrials.gov number, NCT00420784),4 it was 
estimated that virologic response rates with tela-
previr would be 55%, as compared with 29% in 
the control group, in patients who had a relapse 
and 30% versus 8% in patients who had no re-
sponse or a partial response to previous therapy.
One of the secondary end points, the change 
from baseline in log10 HCV RNA levels, was dis-
played over time descriptively and explored with 
the use of a longitudinal statistical model. Sub-
group analyses of sustained virologic response 
according to the stage of liver fibrosis and the 
baseline viral load were conducted to determine 
the robustness of the primary analysis.
R esult s
Patients
Of 833 patients who were screened, 663 underwent 
randomization, and 662 received at least one dose 
of a study drug (intention-to-treat population) (Fig. 
1). The baseline characteristics of the patients and 
their disease level were similar in the three study 
groups (Table 1). A total of 26% of the patients 
had cirrhosis. Overall, 53% of the patients had a 
previous relapse, 19% had a partial response, and 
28% had no response. Baseline telaprevir-resistant 
variants were uncommon (in 12 patients with T54S, 
4 with R155K, and 2 with V36M).
Efficacy
Changes in log10 HCV RNA levels during treat-
ment are shown in Figure 2. The proportion of 
patients who had a sustained virologic response 
was significantly higher in the two telaprevir 
groups than in the control group for patients who 
had a previous relapse (83% in the T12PR48 group, 
88% in the lead-in T12PR48 group, and 24% in the 
control group) and for those who did not have a 
previous virologic response (41%, 41%, and 9%, re-
spectively), including those who had a partial re-
sponse (59%, 54%, and 15%, respectively) and 
those who had no response (29%, 33%, and 5%, 
respectively) (P<0.001 for all comparisons) (Ta-
ble 2). Rates of sustained virologic response were 
similar in the T12PR48 group and the lead-in 
T12PR48 group for patients who had a relapse or 
no response or a partial response to previous ther-
apy. The rate of sustained virologic response was 
also significantly higher for the pooled subgroup 
of patients who had either a relapse or a partial 
response in the telaprevir groups than in the con-
trol group (78% vs. 21%, P<0.001).
Overall, the rates of sustained virologic re-
sponse were 64% in the T12PR48 group, 66% in 
the lead-in T12PR48 group, and 17% in the con-
trol group. The differences in the rates of sus-
tained virologic response were 47 percentage points 
between the T12PR48 group and the control group 
(95% confidence interval [CI], 37 to 57; P<0.001) 
and 50 percentage points between lead-in T12PR48 
group and the control group (95% CI, 40 to 60; 
P<0.001).
Subgroup analyses according to the stage of 
liver fibrosis (Table 2) or baseline viral load (Table 
1 in the Supplementary Appendix) showed higher 
rates of sustained virologic response among pa-
tients receiving telaprevir than among those re-
ceiving peginterferon plus ribavirin alone.
Relapse rates were lower in the two telaprevir 
groups than in the control group among patients 
who had a previous relapse or no response or a 
partial response to previous therapy (Table 2). 
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Among patients who had a relapse, virologic fail-
ure during treatment was observed in 3 patients 
(1%) in the two telaprevir groups and in 18 patients 
(26%) in the control group. Among patients who 
had a previous partial response to therapy, viro-
logic failure was observed in 9 patients (18%) in 
the T12PR48 group, 9 (19%) in the lead-in T12PR48 
group, and 19 (70%) in the control group. For 
patients who had no previous response to therapy, 
virologic failure was observed in 41 patients (57%) 
in the T12PR48 group, 35 (47%) in the lead-in 
T12PR48 group, and 31 (84%) in the control group 
during the overall treatment phase (Table 2).
Among all virologic failures and relapses, 73% 
were associated with the emergence of variants 
with a reduced sensitivity to telaprevir. There were 
no differences in the number or type of emerging 
viral variants between the two telaprevir groups. 
Resistant variants were consistent with those 
that have been reported previously.6 In 60 of 104 
patients (58%) with variants that had a reduced 
sensitivity to telaprevir (primarily in those with 
663 Underwent randomization
833 Patients were screened
266 Were assigned to T12PR48 group,
receiving telaprevir for 12 wk and 
peginterferon and ribavirin for 48 wk
133 Were assigned to the PR48 (control)
group, receiving peginterferon and
ribavirin for 48 wk
1 Did not receive study
drugs because consent
was withdrawn
100 Discontinued at least
1 drug
75 Discontinued telaprevir
79 Discontinued ribavirin
76 Discontinued peginter-
feron
51 Discontinued all 
3 study drugs
Of these 100,
42 Had adverse event
43 Met virologic stopping
rule
15 Had other reasons for
discontinuing
166 (62%) Completed treatment 50 (38%) Completed treatment
264 Were assigned to the lead-in
T12PR48 group, receiving peginterferon
and ribavirin for 4 wk, followed by
telaprevir for 12 wk and peginterferon
and ribavirin up to a total of 48 wk
266 Received at least one dose
of the study drugs
132 Received at least one dose
of the study drugs
264 Received at least one dose
of the study drugs
79 Discontinued at least
1 drug
52 Discontinued telaprevir
65 Discontinued ribavirin
65 Discontinued peginter-
feron
38 Discontinued all
3 study drugs
Of these 79,
34 Had adverse event
35 Met virologic stopping
rule
10 Had other reasons for
discontinuing
82 Discontinued at least
1 drug
44 Discontinued placebo
82 Discontinued ribavirin
82 Discontinued peginter-
feron
44 Discontinued all
3 study drugs
Of these 82,
8 Had adverse event
67 Met virologic stopping
rule
7 Had other reasons for
discontinuing
185 (70%) Completed treatment
171 (64%) Had sustained
virologic response
22 (17%) Had sustained
virologic response
175 (66%) Had sustained
virologic response
Figure 1. Enrollment and Outcomes.
Patients who completed all three study drugs were classified as having completed treatment.
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virologic failure), resistant variants were no longer 
detected by population sequencing at the end of 
the study (median follow-up, 46.4 weeks).
Adverse Events
The most frequently reported adverse events (occur-
ring in more than 25% of patients) in the two tela-
previr groups were fatigue, pruritus, rash, nausea, 
influenza-like illness, anemia, and diarrhea (Ta-
ble 2 in the Supplementary Appendix). Grade 3 
adverse events (mainly anemia, neutropenia, and 
leukopenia) were reported more frequently in the 
two telaprevir groups than in the control group 
during the overall study period (with a rate of 37% 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
T12PR48  
(N = 266)
Lead-in T12PR48 
(N = 264)
PR48 (Control) 
(N = 132)
Age in years — mean (range) 51 (23–69) 51 (24–70) 50 (21–69)
Body-mass index† 28±5.0 27±4.8 27±4.6
Male sex — no. (%) 183 (69) 189 (72) 88 (67)
Race or ethnic group — no. (%)‡
White 246 (92) 252 (95) 117 (89)
Black 11 (4) 8 (3) 11 (8)
Asian or other 9 (3) 4 (2) 4 (3)
Hispanic 25 (9) 27 (10) 20 (15)
Alanine aminotransferase — IU/liter 88±63 80±56 82±58
Total bilirubin — µmol/liter 12±6 12±5 12±5
Serum albumin — g/liter 41±3 42±3 42±3
Platelet count — per mm3 217,000±67,000 219,000±74,000 221,000±71,000
HCV genotype 1 subtype — no. (%)§
1a 118 (44) 121 (46) 59 (45)
1b 121 (45) 115 (44) 59 (45)
1c 0 0 1 (1)
Unknown 27 (10) 28 (11) 13 (10)
HCV RNA log10 — IU/ml¶‖ 6.6±0.03 6.6±0.04 6.6±0.05
HCV RNA ≥800,000 IU/ml — no. (%)¶ 238 (89) 234 (89) 114 (86)
Stage of fibrosis or cirrhosis — no. (%)**
No or minimal fibrosis 51 (19) 68 (26) 35 (27)
Portal fibrosis 83 (31) 71 (27) 38 (29)
Bridging fibrosis 60 (23) 58 (22) 29 (22)
Cirrhosis 72 (27) 67 (25) 30 (23)
Previous type of response — no. (%)
No response 72 (27) 75 (28) 37 (28)
Partial response 49 (18) 48 (18) 27 (20)
Relapse 145 (55) 141 (53) 68 (52)
* Plus–minus values are means ±SD unless otherwise indicated. There were no significant differences among the study 
groups for any characteristic. Percentages may not total 100 because of rounding.
† Body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Race or ethnic group was self-reported. Patients of any race could also identify themselves as Hispanic.
§ The HCV genotype and subtype were determined with the use of the Trugene HCV genotyping assay (Siemens) except 
for one patient in the lead-in T12PR48 group, in whom the subtype was determined with the use of an NS3 assay.
¶  HCV RNA levels were measured with the use of the COBAS TaqMan HCV assay, version 2.0 (Roche).
‖ Log10 values for HCV RNA are means ±SE.
** Patients were grouped into four categories of fibrosis, according to the following Metavir and Ishak fibrosis scores: 
minimal or no fibrosis (Metavir, F0–F1; Ishak, 0–2), portal fibrosis (Metavir, F2; Ishak, 3), bridging fibrosis (Metavir, 
F3; Ishak, 4), and cirrhosis (Metavir, F4; Ishak, 5–6).
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vs. 22%). Serious adverse events and adverse events 
leading to permanent discontinuation of a study 
drug (mainly anemia in both cases) were also 
more frequent in the two telaprevir groups than 
in the control group. In the two telaprevir groups, 
the rate of serious adverse events was 12% and the 
rate of adverse events leading to permanent dis-
continuation of a study drug was 13%, as com-
pared with rates of 5% and 3%, respectively, in 
the control group (Table 3).
In the two telaprevir groups, the rate of grade 
3 rash was 3%, and the rate of grade 3 pruritus was 
1%, as compared with no patients in the control 
group. Rash as an adverse event of special interest 
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Figure 2. Changes in HCV RNA Levels in Patients with a Previous Relapse or No Response or a Partial Response.
Shown are changes in mean log10 HCV RNA levels over the 48-week study period in patients who had a previous 
relapse (Panel A) or no response or a partial response to previous therapy (Panel B). After the initiation of telaprevir 
(at baseline in the T12PR48 group and after 4 weeks in the lead-in T12PR48 group), reductions in levels of HCV RNA 
were greater in the two telaprevir groups than in the PR48 (control) group at all time points except during weeks 36 
and 48 in patients with a previous relapse in the two telaprevir groups and during week 4 in the lead-in T12PR48 
group. The I bars indicate standard errors.
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(i.e., a grade 3 skin event, any skin event resulting 
in permanent discontinuation of any or all study 
drugs, or any skin event defined as a serious ad-
verse event) occurred in 5% of patients in the two 
telaprevir groups, as compared with no patients 
in the control group. In the two telaprevir groups, 
4% of patients discontinued telaprevir and 1% of 
patients discontinued all drugs because of rash. 
No patients discontinued treatment because of 
rash in the control group.
Discussion
Telaprevir in combination with peginterferon alfa-
2a plus ribavirin significantly improved the rates 
of sustained virologic response for patients who 
had received previous therapy for HCV infection. 
As in previous trials,4,5,7 the rates of sustained 
virologic response differed among patients who 
had a previous relapse, those who had no response 
to previous therapy, and those who had a partial 
response. In another study,8 investigators found 
improved rates of sustained virologic response 
for patients who had a previous relapse or partial 
response after the addition of boceprevir, anoth-
er HCV serine protease inhibitor, to peginterfer-
on alfa-2b plus ribavirin. Unlike the study of bo-
ceprevir, our study also included patients who had 
no response to previous therapy (i.e., a reduction 
of <2 log10 in HCV RNA at week 12). In these 
patients, telaprevir combined with peginterferon 
plus ribavirin increased the rate of sustained vi-
Table 2. Key Virologic End Points, According to Previous Treatment Response and Histologic Characteristics.*
Subgroup and End Point T12PR48 Lead-in T12PR48 PR48 (Control)
no./total no. (%)
Previous relapse
Undetectable viral load
At 4 wk 101/145 (70) 4/141 (3) 2/68 (3)
At 8 wk 135/145 (93) 126/141 (89) 7/68 (10)
Sustained virologic response
All patients 121/145 (83)† 124/141 (88)† 16/68 (24)
Patients with undetectable viral load
At 4 wk 91/101 (90) 4/4 (100) 2/2 (100)
At 8 wk 121/135 (90) 116/126 (92) 7/7 (100)
Patients with bridging fibrosis or cirrhosis‡ 54/64 (84) 47/55 (85) 4/30 (13)
Relapse at 72 wk§ 10/135 (7) 9/138 (7) 30/46 (65)
Virologic failure¶ 2/145 (1) 1/141 (1) 18/68 (26)
No response or partial response to previous  
therapy
Sustained virologic response 50/121 (41)† 51/123 (41)† 6/64 (9)
Previous partial response
Undetectable viral load
At 4 wk 32/49 (65) 0 0
At 8 wk 40/49 (82) 31/48 (65) 0
Sustained virologic response
All patients 29/49 (59)† 26/48 (54)† 4/27 (15)
Patients with undetectable viral load
At 4 wk 23/32 (72) NA NA
At 8 wk 27/40 (68) 18/31 (58) NA
Patients with bridging fibrosis or cirrhosis‡ 11/25 (44) 10/25 (40) 1/10 (10)
Relapse at 72 wk§ 8/39 (21) 9/36 (25) 0
Virologic failure¶ 9/49 (18) 9/48 (19) 19/27 (70)
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rologic response from 5% to a range of 29 to 
33%. Even though this therapy increased the rate 
of sustained virologic response by nearly six times, 
further improvements are warranted.
Among patients who have had no response or 
a partial response to previous therapy, those with 
a high baseline viral load and advanced liver fi-
brosis have disease that is particularly difficult 
to cure.9,10 In our study, more than 85% of pa-
tients had a high baseline viral load (i.e., above 
800,000 IU per milliliter), 26% had liver cirrho-
sis, and 22% had bridging fibrosis. No specific 
safety and tolerability issues were associated with 
the use of telaprevir in patients with an advanced 
stage of liver fibrosis, and in such patients the 
rates of sustained virologic response were higher 
in the telaprevir groups than in the control group. 
Although the baseline viral load was not a sig-
nificant prognostic factor for rates of sustained 
virologic response among patients receiving tela-
previr, the presence of advanced fibrosis appeared 
to have a negative effect on the rates of sustained 
virologic response among patients who had no 
response or a partial response to previous thera-
py, although there was no such effect on those who 
had a previous relapse.
We investigated the role of a 4-week lead-in 
phase with peginterferon alfa-2a plus ribavirin 
before the addition of telaprevir. In a smaller study 
of boceprevir, it seemed that lowering of the viral 
load with pretreatment with peginterferon alfa-2b 
plus ribavirin may have reduced the emergence of 
protease-resistant variants, lowered the rate of vi-
rologic breakthrough during treatment, and im-
proved the rate of sustained virologic response.11 
However, we did not observe any significant dif-
ferences between the concurrent and delayed ini-
tiation of telaprevir with peginterferon plus ribavi-
rin in the rates of sustained virologic response.
Overall, virologic failure rates during therapy 
were lower in patients who had a previous relapse 
or a partial response than in patients who had no 
response to previous therapy. Selection and per-
sistence of drug-resistant variants is a common 
concern in the use of direct-acting antiviral agents.12 
As described previously4,13,14 and implemented in 
the present study, strict application of stopping 
rules may help to avoid the selection and long-term 
Table 2. (Continued.)
Subgroup and End Point T12PR48 Lead-in T12PR48 PR48 (Control)
no./total no. (%)
No previous response
Undetectable viral load
At 4 wk 19/72 (26) 0 1/37 (3)
At 8 wk 34/72 (47) 31/75 (41) 1/37 (3)
Sustained virologic response
All patients 21/72 (29)† 25/75 (33)† 2/37 (5)
Patients with undetectable viral load
At 4 wk 10/19 (53) NA 1/1 (100)
At 8 wk 20/34 (59) 21/31 (68) 1/1 (100)
Patients with bridging fibrosis or cirrhosis‡ 12/43 (28) 10/45 (22) 1/19 (5)
Relapse at 72 wk§ 8/30 (27) 9/36 (25) 3/5 (60)
Virologic failure¶ 41/72 (57) 35/75 (47) 31/37 (84)
* Data are for all patients who received at least one dose of a study drug. NA denotes not applicable because there were 
no patients in this group with undetectable HCV RNA at the corresponding earlier time point (at 4 or 8 weeks).
† P<0.001 for the comparison with the control group by means of logistic-regression analysis.
‡ Statistical models showed that there was no significant association between the baseline viral load and sustained viro-
logic response. The stage of liver fibrosis was shown to have a significant effect on outcome, particularly among pa-
tients who had no response or a partial response to previous therapy.
§ Values are for patients who had undetectable HCV RNA at the end of the assigned treatment.
¶ A determination of virologic failure was based on either viral breakthrough or discontinuation of a study drug because 
of meeting a virologic stopping rule.
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persistence of HCV variants with telaprevir resis-
tance. Furthermore, in 58% of patients who had 
variants with reduced sensitivity to telaprevir, such 
variants were no longer detectable by population 
sequencing at the end of the study.
The safety profile of telaprevir with peginter-
feron plus ribavirin was consistent across all phase 
2 and phase 3 trials, which included more than 
2800 patients.4,5,13-17 The addition of telaprevir 
to peginterferon plus ribavirin was particularly 
associated with increased rates of fatigue, gas-
trointestinal side effects, pruritus, and rash4,13,14 
and was associated with an increase of 8 to 12 
percentage points in discontinuation rates, as com-
pared with placebo. Among patients receiving tela-
previr, 4% discontinued telaprevir and 1% discon-
tinued all study drugs because of rash. Although 
combining telaprevir with peginterferon plus riba-
virin also increased the anemia rate, the rate of 
discontinuation of all study drugs because of ane-
mia was low (1%), despite the prohibition of the 
use of erythropoietin-stimulating agents. A post 
hoc analysis showed that reductions in the dose 
of ribavirin in order to manage anemia were not 
associated with a decrease in rates of sustained 
virologic response (data not reported).
The presence of interleukin-28B genetic poly-
morphisms have been shown to be a key predictor 
of the response to peginterferon plus ribavirin in 
patients with HCV infection.18,19 A potential limi-
Table 3. Reasons for Discontinuation of Telaprevir or Placebo and the Incidence of the Most Common Serious Adverse 
Events.*
Variable
T12PR48 
(N = 266)
Lead-in T12PR48 
(N = 264)
PR48 (Control) 
(N = 132)
no. (%)
Reason for discontinuation†
Any adverse event 39 (15) 29 (11) 4 (3)
Rash‡ 12 (5) 10 (4) 0
Anemia‡ 6 (2) 9 (3) 0
Pruritus‡ 1 (<1) 3 (1) 0
Serious adverse event
Any 33 (12) 32 (12) 7 (5)
Blood or lymphatic system disorder
Any 8 (3) 7 (3) 1 (1)
Anemia 6 (2) 7 (3) 1 (1)
Infection 6 (2) 9 (3) 2 (2)
Bronchitis 2 (1) 0 0
Sepsis 0 2 (1) 0
Skin or subcutaneous-tissue disorder
Any 3 (1) 5 (2) 0
Toxic skin eruption 0 2 (1) 0
Cardiac disorder
Any 5 (2) 2 (1) 1 (1)
Acute myocardial infarction 3 (1) 0 0
Atrial fibrillation 0 2 (1) 1 (1)
Gastrointestinal disorder 4 (2) 3 (1) 2 (2)
Neoplasm (benign, malignant, or unspecified,  
including cysts and polyps)
Any 3 (1) 4 (2) 0
Gastric cancer 0 2 (1) 0
Hepatic malignant neoplasm 2 (1) 0 0
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tation of our study was that patients were not 
randomly assigned according to this marker, since 
it had not been discovered at the time of enroll-
ment. However, consent for genetic testing was 
collected from a sizable proportion of patients. 
Since consent for genetic testing requires the de-
identification of samples and analysis by an inde-
pendent group, results for interleukin-28B testing 
are not part of our study.
In conclusion, the addition of telaprevir to peg-
interferon alfa-2a plus ribavirin significantly in-
creased the rates of sustained virologic response 
for patients who are chronically infected with HCV 
genotype 1 and in whom peginterferon plus riba-
virin had failed to achieve viral eradication, includ-
ing those with a high viral load, severe liver fibro-
sis, and cirrhosis. The safety profile of telaprevir 
was consistent with the findings in previous trials.
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Table 3. (Continued.)
Variable
T12PR48 
(N = 266)
Lead-in T12PR48 
(N = 264)
PR48 (Control) 
(N = 132)
no. (%)
Injury, poisoning, or procedural complication 1 (<1) 3 (1) 0
Nervous system disorder 1 (<1) 3 (1) 2 (2)
General disorder or injection-site condition 1 (<1) 2 (1) 0
Psychiatric disorder 0 3 (1) 0
Renal or urinary disorder 3 (1) 0 0
Corticotropin insufficiency 1 (<1) 0 0
Metabolic or nutritional disorder 3 (1) 0 0
Decrease in laboratory value
Hemoglobin
To 8.5 to ≤10 g/dl 71 (27) 73 (28) 20 (15)
To <8.5 g/dl 28 (11) 36 (14) 7 (5)
Neutrophil count
Grade 3 54 (20) 49 (19) 18 (14)
Grade 4 8 (3) 11 (4) 6 (5)
* Listed are serious adverse events that occurred in at least two patients in a study group.
† These discontinuations all occurred during the phase of the study in which telaprevir or placebo was being administered. 
Of the patients who discontinued telaprevir, 22 in the T12PR48 group and 18 in the lead-in T12PR48 group continued 
treatment with peginterferon plus ribavirin. (Details regarding discontinuations of peginterferon, ribavirin, and all study 
drugs together are available in Table 3 in the Supplementary Appendix.)
‡ Included in this category are all related events that were described with a variety of descriptive terms.
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